As anticipated, a big download and it all looks very positive.
Main takeaways for me,
- the last para "The coming months will be pivotal etc"
- one unoptimised (PYC) iMYC candidate bound twice as strongly compared to the gold standard MYC inhibitor
- more new candidates being evaluated in coming weeks
- in-vitro experiments are being undertaken
- the company is now being advised by a panel of international drug discovery experts
- 2 new NDA (confidentially agreements) have been signed with international companies
- Chris Torrance quote (from Cambridge) was very positive
- Genentech discussions continue with indications that they may licence (big up front payment then) or extend option ... before 2016! year end. Interesting that there was no suggestion that option 3, (they walk away) mooted.
A very interesting period ahead.
PYC Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)